Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study

BACKGROUND: Long-term combination antiretroviral therapy often results in toxicity/tolerability problems, which are one of the main reasons for switching treatment. Despite the favorable profile of raltegravir (RAL), data on its combination with abacavir/lamivudine (ABC/3TC) are scarce. Based on cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Troya, Jesús, Montejano, Rocio, Ryan, Pablo, Gómez, Cristina, Matarranz, Mariano, Cabello, Alfonso, Vera, Francisco, Sepúlveda, María Antonia, Santos, Ignacio, Samperiz, Gloria, Bachiller, Pablo, Boix, Vicente, Barrufet, Pilar, Cervero, Miguel, Sanz, José, Solís, Javier, Yllescas, María, Valencia, Eulalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002106/
https://www.ncbi.nlm.nih.gov/pubmed/29902204
http://dx.doi.org/10.1371/journal.pone.0198768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002106/
https://www.ncbi.nlm.nih.gov/pubmed/29902204
http://dx.doi.org/10.1371/journal.pone.0198768

Ejemplares similares